EUVIMEDEUVIMED entdecken
Crossref

Phase 1 trial suggests benefit of psilocybin in OCD treatment

The Brown University Psychopharmacology Update · 2026-08 · 37 (8) · 3-4

DOI: 10.1002/pu.31474 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 28.06.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A Phase 1 trial comprising 15 patients has found that repeated high‐dose administration of psilocybin was more effective than low‐dose psilocybin or placebo in reducing symptoms of obsessive‐compulsive disorder (OCD). Psilocybin was generally well‐tolerated, with no reports of serious adverse events.

Zitieren

APA

(2026). Phase 1 trial suggests benefit of psilocybin in OCD treatment. The Brown University Psychopharmacology Update, 37(8), 3-4. https://doi.org/10.1002/pu.31474

Vancouver

Phase 1 trial suggests benefit of psilocybin in OCD treatment. The Brown University Psychopharmacology Update. 2026;37(8):3-4. doi:10.1002/pu.31474

BibTeX
@article{euvimed2026,
  title = {Phase 1 trial suggests benefit of psilocybin in OCD treatment},
  journal = {The Brown University Psychopharmacology Update},
  year = {2026},
  volume = {37},
  number = {8},
  pages = {3--4},
  doi = {10.1002/pu.31474}
}
Kostenlos starten →